At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Çağatay Arslan, Professor and Medical Oncologist at Medical Park İzmir Hospital, delivered a talk on “Chromophobe RCC: Diagnosis and Treatment”.
Dr. Arslan explained that chromophobe RCC, which accounts for about 4% of kidney cancers, is typically diagnosed at localized stages, often incidentally, and has a better prognosis compared to clear cell RCC. He reviewed its distinct pathological and molecular features, including characteristic chromosomal losses, high KIT expression, and unique genetic alterations identified through TCGA studies.
In terms of treatment, surgery remains the standard of care for localized disease, with minimally invasive approaches and SBRT as options in select patients. He noted that systemic treatment evidence in chromophobe RCC is limited, with most trials including only small patient subsets, but emerging studies may clarify the role of immunotherapy and targeted approaches in the adjuvant and metastatic settings.
Join us in this conversation.